Exelixis

EXEL

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Exelixis has been a target of short sellers for a while. The current short interest of 11.57% is roughly at the average of the last 12 months (10.59%).